January 2025
Bayer Prepares for Critical Challenges Amid Xarelto Decline
Bayer, Xarelto, patent expirations, generic competition, pharmaceutical industry, earnings decline, strategic plans, JPM25
Appeals Court Upholds FDA’s Denial of Fast Track Designation for Vanda’s Gastroparesis Drug
FDA, Vanda Pharmaceuticals, Fast Track Designation, Gastroparesis, Drug Approval Process
Servier and Google Cloud Extend Partnership to Accelerate AI-Powered Drug Development
Servier, Google Cloud, AI, drug development, pharmaceutical research, digital transformation, R&D, generative AI, gen AI, therapeutic solutions.
FDA Rejects Atara’s Ebvallo Due to Manufacturing Issues, Not Efficacy or Safety Concerns
Atara Therapeutics, Ebvallo, FDA rejection, manufacturing issues, post-transplant lymphoproliferative disease (PTLD), Epstein-Barr virus (EBV), T-cell immunotherapy, Pierre Fabre Laboratories.
Charles River Laboratories Forecasts Revenue Decline in 2025 Amid CDMO Challenges
Charles River Laboratories, CRL, 2025 revenue outlook, CDMO business challenges, biopharma spending constraints, pharmaceutical industry trends
Denmark’s AI and Biotech Advancements: No Direct Information on New Manufacturing Learning Center
Denmark, AI research center, biotech acquisitions, vocational education, manufacturing learning center
DEA Unveils Special Registration Framework for Telehealth Prescribing of Controlled Substances
DEA Special Registration, Telehealth Prescribing, Controlled Substances, Telemedicine Flexibilities, Ryan Haight Act, Telemedicine Regulations
FDA Approves Lilly’s Omvoh for Crohn’s Disease, Expanding Treatment Options
Omvoh, FDA approval, Crohn’s disease, inflammatory bowel disease, mirikizumab-mrkz, Eli Lilly
NVIDIA’s AI Innovations: Pioneering the Future of Artificial Intelligence
NVIDIA AI Innovations, Generative AI, Accelerated Computing, Robotics, AI in Healthcare, AI Foundation Models
Hinge Bio Secures $30 Million Series A’ Financing for Next-Generation Therapies via GEM-DIMER Platform
Hinge Bio, immune reset, GEM-DIMER platform, Series A’ financing, autoimmune diseases, HB2198, Systemic Lupus Erythematosus